Description:Delos Capital is a prominent investment firm specializing in the life sciences sector, dedicated to partnering with exceptional teams that are engaged in the development of breakthrough medicines aimed at significantly enhancing the lives of patients. The firm operates as a collaborative global entity comprising seasoned biotech investors, company builders, operators, and industry analysts. Its primary objective is to provide meaningful support to the companies it invests in by delivering not only capital but also extensive biotech expertise.
Delos Capital has a proven track record in designing, building, financing, and supporting both innovative platforms and approved medications, impacting the lives of hundreds of millions around the globe. The firm is guided by a commitment to enable the creation of high-value medicines and maintains a modality-agnostic approach, working across various therapeutic areas. This enables Delos Capital to partner with a diverse range of companies, from early-stage discovery platforms to those actively engaged in clinical development.
The firm’s global team is strategically located across offices in Cambridge, Massachusetts, and East Asia, allowing them to effectively merge deep operational experiences at the heart of global biotech ventures with unique insights into innovations emerging from burgeoning biotech clusters. Through this comprehensive approach, Delos Capital continues to play a vital role in advancing life sciences and fostering advancements that promise to improve patient outcomes worldwide.